Very-long-chain Acyl-CoA Synthetases
Year: 2007
Type: review
Abstract: Activation of fatty acids by thioesterification to coenzyme A is a fundamental metabolic process that can be found in all organisms from Archaea to man (1Watkins P.A. Prog. Lipid Res. 1997; 36: 55-83Crossref PubMed Scopus (153) Google Scholar). Formation of acyl-CoA allows an otherwise non-reactive fatty acid to participate in biosynthetic or catabolic pathways. This two-step reaction is catalyzed by acyl-CoA synthetase (ACS 2The abbreviations used are: ACSacyl-CoA synthetaseVLCFAvery-long-chain fatty acidX-ALDX-linked adrenoleukodystrophyACSVLvery-long-chain ACSFATPfatty acid transport proteinTHCAtrihydroxycholestanoic acidPPARperoxisome proliferator-activated receptor. 2The abbreviations used are: ACSacyl-CoA synthetaseVLCFAvery-long-chain fatty acidX-ALDX-linked adrenoleukodystrophyACSVLvery-long-chain ACSFATPfatty acid transport proteinTHCAtrihydroxycholestanoic acidPPARperoxisome proliferator-activated receptor.; EC 6.2.1.x). Fattyacid+ATP+Mg2+→acyl-AMP+Mg2++PPiAcyl-AMP+CoASH→acyl-CoA+AMP As early as 1953, it was recognized that there were at least three enzymes with ACS activity, activating short-chain (2–3 carbons), medium-chain (4–12 carbons), and long-chain (≥12 carbons) fatty acid substrates (1Watkins P.A. Prog. Lipid Res. 1997; 36: 55-83Crossref PubMed Scopus (153) Google Scholar).The need for enzymes capable of activating saturated very-long-chain fatty acids (VLCFAs; containing ≥22 carbons) became evident with the discovery of elevated VLCFA levels in X-linked adrenoleukodystrophy (X-ALD) and other peroxisomal disorders (2Moser A.B. Kreiter N. Bezman L. Lu S. Raymond G.V. Naidu S. Moser H.W. Ann. Neurol. 1999; 45: 100-110Crossref PubMed Scopus (285) Google Scholar). Formation of VLCFA-CoA is essential for degrading excess VLCFA via peroxisomal β-oxidation. Singh et al. (3Singh I. Kang M.S. Phillips L.A. Fed. Proc. 1982; 41: 1192Google Scholar) were the first to demonstrate that rat brain microsomes could activate the VLCFA lignoceric acid (C24:0).Although purification of an enzyme with very-long-chain ACS (ACSVL) activity from mammalian tissues proved to be challenging, Hashimoto and co-workers (4Uchida Y. Kondo N. Orii T. Hashimoto T. J. Biochem. (Tokyo). 1996; 119: 565-571Crossref PubMed Scopus (48) Google Scholar) were successful. By following C24:0 activation, they achieved a 479-fold purification of a 70-kDa protein from rat liver peroxisomes. cDNA encoding this enzyme was cloned and expressed in COS-1 cells, yielding an enzymatically active protein (5Uchiyama A. Aoyama T. Kamijo K. Uchida Y. Kondo N. Orii T. Hashimoto T. J. Biol. Chem. 1996; 271: 30360-30365Abstract Full Text Full Text PDF PubMed Scopus (121) Google Scholar). The endogenous enzyme localized to peroxisomes and microsomes and was found only in liver and kidney; thus, earlier reports of ACSVL activity in brain suggested the existence of additional enzyme(s) (3Singh I. Kang M.S. Phillips L.A. Fed. Proc. 1982; 41: 1192Google Scholar).Two years prior to the purification and cloning of ACSVL, Schaffer and Lodish (6Schaffer J.E. Lodish H.F. Cell. 1994; 79: 427-436Abstract Full Text PDF PubMed Scopus (736) Google Scholar) independently cloned cDNA encoding a novel protein that they called "fatty acid transport protein" (FATP). FATP was identified, along with a long-chain ACS, when a cDNA library was screened for proteins that augmented uptake of a fluorescent fatty acid, C1-BODIPY-C12, by 3T3-L1 adipocytes. mRNA encoding this 63-kDa protein was also expressed in heart, skeletal muscle, brain, and kidney. When overexpressed in 3T3 cells, FATP was associated with the plasma membrane fraction and stimulated the uptake of radiolabeled palmitic (C16:0), oleic (C18:1), and arachidonic (C20:4) acids, thereby displaying many of the properties expected for a transporter. When the ACSVL amino acid sequence of Hashimoto and co-workers (5Uchiyama A. Aoyama T. Kamijo K. Uchida Y. Kondo N. Orii T. Hashimoto T. J. Biol. Chem. 1996; 271: 30360-30365Abstract Full Text Full Text PDF PubMed Scopus (121) Google Scholar) was compared with data base sequences, the protein it was most homologous to was not, as expected, long-chain or other ACSs, but rather FATP. Thus began a controversy as to whether FATP and related proteins are ACSs, fatty acid transporters, or both; this controversy remains, in part, unresolved.The ACSVL Enzyme FamilyProteins orthologous and paralogous to ACSVL and FATP have been identified in many species. The ACSVL 3The suggested, unofficial ACSVL nomenclature (Table 1) conforms with the approved nomenclature for short-, medium-, and long-chain and "bubble gum" ACS families. family in humans and rodents contains six proteins (Table 1) (7Hirsch D. Stahl A. Lodish H.F. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 8625-8629Crossref PubMed Scopus (366) Google Scholar, 8Watkins P.A. Pevsner J. Steinberg S.J. Prostaglandins Leukot. Essent. Fatty Acids. 1999; 60: 323-328Abstract Full Text PDF PubMed Scopus (47) Google Scholar, 9Steinberg S.J. Morgenthaler J. Heinzer A.K. Smith K.D. Watkins P.A. J. Biol. Chem. 2000; 275: 35162-35169Abstract Full Text Full Text PDF PubMed Scopus (102) Google Scholar). Zebrafish (Danio rerio), fruit fly (Drosophila melanogaster), and roundworm (Caenorhabditis elegans) ACSVL families have eight, six, and two proteins, respectively (10Watkins P.A. Maiguel D. Jia Z. Pevsner J. J. Lipid Res. 2007; 48: 2736-2750Abstract Full Text Full Text PDF PubMed Scopus (232) Google Scholar), whereas a yeast (Saccharomyces cerevisiae) and a bacterium (Mycobacterium tuberculosis) have only a single homologous protein (7Hirsch D. Stahl A. Lodish H.F. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 8625-8629Crossref PubMed Scopus (366) Google Scholar, 11Watkins P.A. Lu J.F. Steinberg S.J. Gould S.J. Smith K.D. Braiterman L.T. J. Biol. Chem. 1998; 273: 18210-18219Abstract Full Text Full Text PDF PubMed Scopus (133) Google Scholar). The six human ACSVL proteins (containing 619–730 amino acids) share 37–59% identity but are only 17–25% identical to other human ACSs (10Watkins P.A. Maiguel D. Jia Z. Pevsner J. J. Lipid Res. 2007; 48: 2736-2750Abstract Full Text Full Text PDF PubMed Scopus (232) Google Scholar). All enzymatically active ACSs have two conserved amino acid sequence domains: a 10-residue AMP-binding domain (Motif I) that is highly conserved from bacteria to man (9Steinberg S.J. Morgenthaler J. Heinzer A.K. Smith K.D. Watkins P.A. J. Biol. Chem. 2000; 275: 35162-35169Abstract Full Text Full Text PDF PubMed Scopus (102) Google Scholar) and a recently revised 35-residue domain (Motif II) containing a sequence originally proposed as a fatty acid-binding "signature motif" (10Watkins P.A. Maiguel D. Jia Z. Pevsner J. J. Lipid Res. 2007; 48: 2736-2750Abstract Full Text Full Text PDF PubMed Scopus (232) Google Scholar). Motif II has been used to assign ACSs to subfamilies (9Steinberg S.J. Morgenthaler J. Heinzer A.K. Smith K.D. Watkins P.A. J. Biol. Chem. 2000; 275: 35162-35169Abstract Full Text Full Text PDF PubMed Scopus (102) Google Scholar).TABLE 1Nomenclature and properties of human and rodent family ACSVLsApproved gene symbolACS nomenclatureFATP nomenclatureOther aliasesTissue expressionKnown substratesSLC27A1ACSVL4FATP1FATPHeart, adipose, muscle, brainC16:0, C18:1, C24:0SLC27A2ACSVL1FATP2VLCS, VLACSLiver, kidneyC16:0, C24:0, THCA, phytanic acid, pristanic acidSLC27A3ACSVL3FATP3Testis, adrenal gland, ovary, brain, lung, kidneyC16:0, C18:1, C24:0SLC27A4ACSVL5FATP4Small intestine, skin, brain, adipose, muscle, heart, liver, kidneyC24:0 (C16:0)SLC27A5ACSVL6FATP5ACSB, BACS, VLCS-H2, VLACSRLiverCholate, chenodeoxycholate, deoxycholate, lithocholate, THCA (C24:0)SLC27A6ACSVL2FATP6VLCS-H1Heart, placentaC18:1, C20:4, C24:0 Open table in a new tab Examination of the crystal structure of Thermus thermophilus long-chain ACS suggests that Motif II may not be involved in chain length recognition. Its fatty acid-binding tunnel is formed by four separate smaller domains located between Motifs I and II (12Hisanaga Y. Ago H. Nakagawa N. Hamada K. Ida K. Yamamoto M. Hori T. Arii Y. Sugahara M. Kuramitsu S. Yokoyama S. Miyano M. J. Biol. Chem. 2004; 279: 31717-31726Abstract Full Text Full Text PDF PubMed Scopus (165) Google Scholar). A conserved arginine residue at the center of Motif II interacts with the 3′-hydroxyl group of AMP and not the fatty acid (10Watkins P.A. Maiguel D. Jia Z. Pevsner J. J. Lipid Res. 2007; 48: 2736-2750Abstract Full Text Full Text PDF PubMed Scopus (232) Google Scholar, 13Pei Z. Jia Z. Watkins P.A. J. Biol. Chem. 2006; 281: 6632-6641Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar). Although this motif may not dictate fatty acid substrate specificity, enzymes grouped into subfamilies of short-, medium-, and long-chain enzymes using Motif II seem to prefer these substrates (1Watkins P.A. Prog. Lipid Res. 1997; 36: 55-83Crossref PubMed Scopus (153) Google Scholar, 10Watkins P.A. Maiguel D. Jia Z. Pevsner J. J. Lipid Res. 2007; 48: 2736-2750Abstract Full Text Full Text PDF PubMed Scopus (232) Google Scholar). In contrast, the enzymes grouped as ACSVLs have all been shown to be capable of activating C24:0, which is a poor substrate for other ACSs. Inspection of human ACS regions homologous to domains forming the T. thermophilus ACS fatty acid-binding pocket did not suggest that they contain features useful for predicting substrate specificity. 4P. A. Watkins, unpublished data. At present, therefore, substrate utilization must be established experimentally.Like other ACSs, the ACSVL proteins differ in their tissue expression patterns, subcellular locations, and substrate specificities, suggesting that each plays a unique role in lipid metabolism. This minireview will focus on mammalian ACSVLs.ACSVL1—ACSVL1 (also known as VLCS, VLACS, and FATP2) (Table 1) is the enzyme purified by Hashimoto and co-workers (5Uchiyama A. Aoyama T. Kamijo K. Uchida Y. Kondo N. Orii T. Hashimoto T. J. Biol. Chem. 1996; 271: 30360-30365Abstract Full Text Full Text PDF PubMed Scopus (121) Google Scholar). It is expressed mainly in liver and kidney and has been localized to both endoplasmic reticulum membranes and peroxisomes (14Steinberg S.J. Wang S.J. Kim D.G. Mihalik S.J. Watkins P.A. Biochem. Biophys. Res. Commun. 1999; 257: 615-621Crossref PubMed Scopus (117) Google Scholar). When overexpressed in COS-1 cells, human ACSVL1 activates C16:0 and C24:0 and the branched-chain fatty acids phytanic and pristanic acids. In peroxisomes, ACSVL1 is oriented facing the matrix, suggesting that it could activate pristanic acid, generated by phytanic acid α-oxidation, to its CoA derivative for further degradation via peroxisomal β-oxidation. Although the level of ACSVL1 in microsomes is almost 10-fold greater than that in peroxisomes, its microsomal function remains obscure. Trihydroxycholestanoic acid (THCA) is also a substrate for ACSVL1, implicating this enzyme in the de novo synthesis of bile acids from cholesterol (15Mihalik S.J. Steinberg S.J. Pei Z. Park J. Kim D.G. Heinzer A.K. Dacremont G. Wanders R.J. Cuebas D.A. Smith K.D. Watkins P.A. J. Biol. Chem. 2002; 277: 24771-24779Abstract Full Text Full Text PDF PubMed Scopus (84) Google Scholar). However, it is unclear whether this process takes place in peroxisomes or microsomes (Fig. 1).An ACSVL1 knock-out mouse was produced that was viable, fertile, and exhibited no obvious phenotypic abnormalities. Liver and kidney peroxisomes from this mouse had reduced rates of VLCFA β-oxidation, yet plasma and tissue VLCFA levels were normal (16Heinzer A.K. Watkins P.A. Lu J.F. Kemp S. Moser A.B. Li Y.Y. Mihalik S. Powers J.M. Smith K.D. Hum. Mol. Genet. 2003; 12: 1145-1154Crossref PubMed Scopus (76) Google Scholar). Although decreased peroxisomal ACSVL activity was reported in fibroblasts from patients with the neurodegenerative disease X-ALD, no changes in ACSVL1 expression were found either in these cells or in X-ALD mouse tissues (17Jia Z. Pei Z. Li Y. Wei L. Smith K.D. Watkins P.A. Mol. Genet. Metab. 2004; 83: 117-127Crossref PubMed Scopus (22) Google Scholar).ACSVL2—Human ACSVL2 (VLCS-H1 and FATP6) (Table 1) cDNA has been cloned previously (8Watkins P.A. Pevsner J. Steinberg S.J. Prostaglandins Leukot. Essent. Fatty Acids. 1999; 60: 323-328Abstract Full Text PDF PubMed Scopus (47) Google Scholar, 18Gimeno R.E. Ortegon A.M. Patel S. Punreddy S. Ge P. Sun Y. Lodish H.F. Stahl A. J. Biol. Chem. 2003; 278: 16039-16044Abstract Full Text Full Text PDF PubMed Scopus (151) Google Scholar). ACSVL2 expression was limited to the heart on Northern blots (18Gimeno R.E. Ortegon A.M. Patel S. Punreddy S. Ge P. Sun Y. Lodish H.F. Stahl A. J. Biol. Chem. 2003; 278: 16039-16044Abstract Full Text Full Text PDF PubMed Scopus (151) Google Scholar). However, expressed sequence tags from human heart, brain, lung, larynx, and ovary libraries have been identified, and the protein has been detected in hair follicle epithelial cells (19Schmuth M. Ortegon A.M. Mao-Qiang M. Elias P.M. Feingold K.R. Stahl A. J. Investig. Dermatol. 2005; 125: 1174-1181Abstract Full Text Full Text PDF PubMed Scopus (66) Google Scholar). Gimeno et al. (18Gimeno R.E. Ortegon A.M. Patel S. Punreddy S. Ge P. Sun Y. Lodish H.F. Stahl A. J. Biol. Chem. 2003; 278: 16039-16044Abstract Full Text Full Text PDF PubMed Scopus (151) Google Scholar) localized the protein to the sarcolemma of cardiac myocytes in mice and rhesus monkeys. Although ACS activity of human ACSVL2 has not been demonstrated, mouse ACSVL2 expressed in a yeast model system activated C18:1, C20:4, and C24:0 (20DiRusso C.C. Li H. Darwis D. Watkins P.A. Berger J. Black P.N. J. Biol. Chem. 2005; 280: 16829-16837Abstract Full Text Full Text PDF PubMed Scopus (113) Google Scholar).ACSVL3—ACSVL3 (FATP3) is the most recently characterized member of the ACSVL family (21Pei Z. Fraisl P. Berger J. Jia Z. Forss-Petter S. Watkins P.A. J. Biol. Chem. 2004; 279: 54454-54462Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar). Mouse ACSVL3 mRNA was found primarily in steroidogenic tissues (adrenal, testis, and ovary) and in brain, and the protein localized to punctate subcellular vesicles that sedimented with mitochondria (21Pei Z. Fraisl P. Berger J. Jia Z. Forss-Petter S. Watkins P.A. J. Biol. Chem. 2004; 279: 54454-54462Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar). Loss-of-function studies in RNA interference-treated mouse MA-10 Leydig cells demonstrated that C16:0 and C24:0 are ACSVL3 substrates and that this enzyme accounts for 30 and 26% of the total cellular activation of these fatty acids, respectively.FATP1—More is currently known about FATP1 (proposed designation ACSVL4), the protein originally called FATP (6Schaffer J.E. Lodish H.F. Cell. 1994; 79: 427-436Abstract Full Text PDF PubMed Scopus (736) Google Scholar), than for the other members of the ACSVL family. FATP1 mRNA is highly expressed in muscle, heart, brain, and adipose tissue (6Schaffer J.E. Lodish H.F. Cell. 1994; 79: 427-436Abstract Full Text PDF PubMed Scopus (736) Google Scholar). When purified to homogeneity following overexpression in COS-1 cells, FATP1 catalyzed the activation of C16:0 and C24:0 (22Hall A.M. Smith A.J. Bernlohr D.A. J. Biol. Chem. 2003; 278: 43008-43013Abstract Full Text Full Text PDF PubMed Scopus (143) Google Scholar). Increased incorporation of fatty acids into triacylglycerol was observed when FATP1 was overexpressed in primary human myocytes or HEK293 cells (23Garcia-Martinez C. Marotta M. Moore-Carrasco R. Guitart M. Camps M. Busquets S. Montell E. Gomez-Foix A.M. Am. J. Physiol. 2005; 288: C1264-C1272Crossref PubMed Scopus (62) Google Scholar, 24Hatch G.M. Smith A.J. Xu F.Y. Hall A.M. Bernlohr D.A. J. Lipid Res. 2002; 43: 1380-1389Abstract Full Text Full Text PDF PubMed Scopus (65) Google Scholar). In myocytes, decreased oxidation of C16:0 or C18:1 to CO2 was also noted. In 293 cells, FATP1 overexpression was accompanied by an increase in 1,2-diacylglycerol acyltransferase activity. Because fatty acid incorporation into glycerophospholipids and sphingomyelin was unaffected by FATP1 overexpression, it was suggested that this protein channels exogenous fatty acids into triacylglycerol biosynthesis. Reduced triacylglycerol deposition in 3T3-L1 adipocytes with short hairpin RNA-induced FATP1 knockdown supports this conclusion (25Lobo S. Wiczer B.M. Smith A.J. Hall A.M. Bernlohr D.A. J. Lipid Res. 2007; 48: 609-620Abstract Full Text Full Text PDF PubMed Scopus (112) Google Scholar). Interestingly, lack of FATP1 did not otherwise affect preadipocyte differentiation.FATP1 expression was increased during adipocyte differentiation in culture both in 3T3-L1 cells and in HIB-1B brown adipocytes (6Schaffer J.E. Lodish H.F. Cell. 1994; 79: 427-436Abstract Full Text PDF PubMed Scopus (736) Google Scholar, 26Wu Q. Kazantzis M. Doege H. Ortegon A.M. Tsang B. Falcon A. Stahl A. Diabetes. 2006; 55: 3229-3237Crossref PubMed Scopus (84) Google Scholar). Insulin had pleiotropic effects on FATP1 expression, with early repression followed by robust stimulation during differentiation and subsequent repression in mature adipocytes (27Man M.Z. Hui T.Y. Schaffer J.E. Lodish H.F. Bernlohr D.A. Mol. Endocrinol. 1996; 10: 1021-1028Crossref PubMed Scopus (69) Google Scholar). Ligands that activate PPARα and PPARγ increased FATP1 expression, but in a tissue-specific manner (28Martin G. Schoonjans K. Lefebvre A.M. Staels B. Auwerx J. J. Biol. Chem. 1997; 272: 28210-28217Abstract Full Text Full Text PDF PubMed Scopus (470) Google Scholar). The β-adrenergic agonist isoproterenol increased FATP1 protein levels in HIB-1B cells (26Wu Q. Kazantzis M. Doege H. Ortegon A.M. Tsang B. Falcon A. Stahl A. Diabetes. 2006; 55: 3229-3237Crossref PubMed Scopus (84) Google Scholar), whereas tumor necrosis factor-α reduced FATP1 expression in 3T3-L1 adipocytes (29Stahl A. Evans J.G. Pattel S. Hirsch D. Lodish H.F. Dev. Cell. 2002; 2: 477-488Abstract Full Text Full Text PDF PubMed Scopus (202) Google Scholar). In brown fat, FATP1 expression was increased by cold exposure, consistent with a role in non-shivering thermogenesis (26Wu Q. Kazantzis M. Doege H. Ortegon A.M. Tsang B. Falcon A. Stahl A. Diabetes. 2006; 55: 3229-3237Crossref PubMed Scopus (84) Google Scholar).Originally reported to be in the plasma membrane of 3T3-L1 cells, subsequent studies indicated that in adipocytes and skeletal muscle cells, FATP1 translocates to the cell surface from an intracellular perinuclear compartment upon insulin stimulation (29Stahl A. Evans J.G. Pattel S. Hirsch D. Lodish H.F. Dev. Cell. 2002; 2: 477-488Abstract Full Text Full Text PDF PubMed Scopus (202) Google Scholar, 30Wu Q. Ortegon A.M. Tsang B. Doege H. Feingold K.R. Stahl A. Mol. Cell. Biol. 2006; 26: 3455-3467Crossref PubMed Scopus (210) Google Scholar). This phenomenon may be tissue-specific, as it was not observed in cardiomyocytes (31Gimeno R.E. Curr. Opin. Lipidol. 2007; 18: 271-276Crossref PubMed Scopus (118) Google Scholar).Topologic studies showed that FATP1 has at least one transmembrane-spanning domain and several membrane-associated domains, with the N terminus oriented toward the extracellular space and the C terminus facing the cytoplasm (32Lewis S.E. Listenberger L.L. Ory D.S. Schaffer J.E. J. Biol. Chem. 2001; 276: 37042-37050Abstract Full Text Full Text PDF PubMed Scopus (74) Google Scholar). Co-immunoprecipitation studies suggested that FATP1 exists as a homodimer that also interacts with the long-chain ACS ACSL1 (33Richards M.R. Listenberger L.L. Kelly A.A. Lewis S.E. Ory D.S. Schaffer J.E. J. Biol. Chem. 2003; 278: 10477-10483Abstract Full Text Full Text PDF PubMed Scopus (34) Google Scholar, 34Richards M.R. Harp J.D. Ory D.S. Schaffer J.E. J. Lipid Res. 2006; 47: 665-672Abstract Full Text Full Text PDF PubMed Scopus (86) Google Scholar). The interaction between FATP1 and ACSL1 was not affected by acute insulin or isoproterenol treatment.A transgenic mouse with heart-specific FATP1 overexpression showed evidence of increased cardiac uptake of labeled C16:0 that was mainly in the free fatty acid pool (35Chiu H.C. Kovacs A. Blanton R.M. Han X. Courtois M. Weinheimer C.J. Yamada K.A. Brunet S. Xu H. Nerbonne J.M. Welch M.J. Fettig N.M. Sharp T.L. Sambandam N. Olson K.M. Ory D.S. Schaffer J.E. Circ. Res. 2005; 96: 225-233Crossref PubMed Scopus (344) Google Scholar). By 3 months of age, these mice developed a lipotoxic cardiomyopathy characterized by electrocardiogram abnormalities, impaired ventricular function, and atrial enlargement to that in FATP1 mice a normal were with no cardiac (31Gimeno R.E. Curr. Opin. Lipidol. 2007; 18: 271-276Crossref PubMed Scopus (118) Google Scholar, H. Stahl A. 2006; PubMed Scopus Google Scholar). However, when a these mice were from insulin in skeletal mice had smaller lipid in brown adipose tissue and were to during cold between FATP1 and and in humans has been A in of the human FATP1 gene is associated with elevated triacylglycerol levels and in K. C. P. S. K. K. A. R.M. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar, A. G. M. S. D. Auwerx J. P. N. Biol. 2000; PubMed Scopus Google Scholar). However, a of reported a in skeletal muscle FATP1 expression, but did not the conclusion that this protein to or C. G. P. M. Auwerx J. H. Am. J. Physiol. 2000; 279: PubMed Google Scholar). A of with found that FATP1 levels with in free fatty acid but that was to a role in K. H. J. A. P. A. R.M. 2004; 47: PubMed Scopus Google (proposed designation and FATP1 are amino acid is expressed in brain, adipose skeletal muscle, heart, and (31Gimeno R.E. Curr. Opin. Lipidol. 2007; 18: 271-276Crossref PubMed Scopus (118) Google Scholar, A. J. Physiol. 2004; PubMed Scopus Google Scholar). When overexpressed in COS-1 cells, activated C16:0 and C24:0 A.M. Wiczer B.M. T. Bernlohr D.A. J. Biol. Chem. 2005; 280: Full Text Full Text PDF PubMed Scopus (118) Google Scholar, T. I. Hall A.M. Bernlohr D.A. 2001; PubMed Scopus Google Scholar). had a substrate specificity. However, brain, intestine, and from an mouse showed a greater in C24:0 activation than in C16:0 activation A.M. Wiczer B.M. T. Bernlohr D.A. J. Biol. Chem. 2005; 280: Full Text Full Text PDF PubMed Scopus (118) Google et al. A. Hirsch Gimeno R.E. Punreddy S. Ge P. N. Patel S. M. A. L.A. Lodish H.F. Mol. Cell. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar) reported that was located in the membrane of mature mouse and suggested that a function of this protein was fatty acid However, the primary in mice was in the skin, function, and in or H. Stahl A. 2006; PubMed Scopus Google Scholar, T. L. I. G. I. G. J. Biol. 2003; PubMed Scopus Google Scholar). is expressed in human and mouse and is found at levels in (19Schmuth M. Ortegon A.M. Mao-Qiang M. Elias P.M. Feingold K.R. Stahl A. J. Investig. Dermatol. 2005; 125: 1174-1181Abstract Full Text Full Text PDF PubMed Scopus (66) Google Scholar). The of mice had decreased levels of and cholesterol and increased In the fatty acid was with increased long-chain and decreased very-long-chain saturated and fatty acids T. L. I. G. I. G. J. Biol. 2003; PubMed Scopus Google fibroblasts from mice activated C24:0 at rates of in normal cells, suggesting that this enzyme is the ACSVL in this cell Z. Pei Z. Watkins P.A. J. Biol. Chem. 2007; Full Text Full Text PDF PubMed Scopus (86) Google Scholar). VLCFA as as incorporation of C24:0 into and cholesterol was reduced by in cells, that the enzyme is in subcellular This was by and studies that the protein associated with peroxisomes, and the endoplasmic but not with the plasma Although studies suggested a plasma membrane for in adipocytes and epithelial cells (29Stahl A. Evans J.G. Pattel S. Hirsch D. Lodish H.F. Dev. Cell. 2002; 2: 477-488Abstract Full Text Full Text PDF PubMed Scopus (202) Google Scholar, A. Hirsch Gimeno R.E. Punreddy S. Ge P. N. Patel S. M. A. L.A. Lodish H.F. Mol. Cell. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar), other studies suggested that the protein localized to intracellular membranes in these cell (25Lobo S. Wiczer B.M. Smith A.J. Hall A.M. Bernlohr D.A. J. Lipid Res. 2007; 48: 609-620Abstract Full Text Full Text PDF PubMed Scopus (112) Google Scholar, K. T. C. D. J. R. Watkins P.A. J. J. Sci. 2006; 119: PubMed Scopus Google Scholar). The of these remains levels were increased in 3T3-L1 cells upon differentiation to yet RNA knockdown did not affect preadipocyte differentiation or FATP1 levels (25Lobo S. Wiczer B.M. Smith A.J. Hall A.M. Bernlohr D.A. J. Lipid Res. 2007; 48: 609-620Abstract Full Text Full Text PDF PubMed Scopus (112) Google Scholar, A. Evans J.G. Pattel S. Hirsch D. Lodish H.F. Dev. Cell. 2002; 2: 477-488Abstract Full Text Full Text PDF PubMed Scopus (202) Google Scholar). was not to the plasma membrane by 3T3-L1 adipocytes with knockdown had reduced triacylglycerol in with the (25Lobo S. Wiczer B.M. Smith A.J. Hall A.M. Bernlohr D.A. J. Lipid Res. 2007; 48: 609-620Abstract Full Text Full Text PDF PubMed Scopus (112) Google Scholar). PPARγ has been in the of as knockdown in adipocytes to increased PPARγ and activation of PPARγ in primary human cells increased expression of (25Lobo S. Wiczer B.M. Smith A.J. Hall A.M. Bernlohr D.A. J. Lipid Res. 2007; 48: 609-620Abstract Full Text Full Text PDF PubMed Scopus (112) Google Scholar, I. M. Y. J. Endocrinol. Metab. 2005; PubMed Scopus Google role for in and insulin has been proposed on the of human In a of levels were found to be in independently of K. H. J. A. P. A. R.M. 2004; 47: PubMed Scopus Google Scholar). In a of for an was associated with a and triacylglycerol and insulin levels K. M. P. S. A. M. R.M. J. Endocrinol. Metab. 2004; PubMed Scopus Google BACS, VLCS-H2, and is a bile that was originally as a of ACSVL1 S.J. Wang S.J. Watkins P.A. Mol. Genet. Metab. 1999; PubMed Scopus Google
Source: Journal of Biological Chemistry
Author: Paul A. Watkins
Language: English
Subfield: Biochemistry
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,430
OpenAlex ID: W1981222875
